Health · 35 views
GLP-1 use among young children with obesity in US remains rare but is rising rapidly
Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, when the drugs were first prescribed, a…
AI Summary
A new study finds that prescriptions of GLP‑1 weight‑loss drugs—Saxenda, Wegovy and Zepbound—for U.S. children under 12 with obesity remain rare, but the number of prescriptions in June 2026 was 310 times higher than in 2019, when the drugs were first prescribed.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Plant-first food pyramid brings international dietary guidelines together in adaptable global guideContinue reading
- Can Reddit help strengthen health communications on extreme heat?Continue reading
- Boom in weight-loss drugs could lead to fall in beer sales, Heineken warns UK pubsContinue reading
- What if you gave yourself a day to cancel all the plans you dread?Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow